McCann, Liza J;
Livermore, Polly;
Wilkinson, Meredyth G Ll;
Wedderburn, Lucy R;
(2022)
Juvenile dermatomyositis. Where are we now?
Clinical and Experimental Rheumatology
, 40
(2)
pp. 394-403.
Preview |
Text
Wedderburn_McCann et al final C Exp Rheum 2022.pdf Download (417kB) | Preview |
Abstract
Juvenile onset idiopathic inflammatory myopathy (IIM) has many similarities and distinct differences from adult-onset disease. This review will focus on recent developments in understanding and treatment of juvenile dermatomyositis (JDM), the most common disease sub-type of IIM in childhood. JDM is a systemic immune mediated vasculopathy, increasingly recognised as a group of distinct phenotypes with variable presentation and outlook. This overview will describe long-term outlook and disease course including health-related quality of life and emerging treatments.
Type: | Article |
---|---|
Title: | Juvenile dermatomyositis. Where are we now? |
Location: | Italy |
Open access status: | An open access version is available from UCL Discovery |
Publisher version: | https://www.clinexprheumatol.org/abstract.asp?a=17... |
Language: | English |
Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
Keywords: | Dermatomyositis, Disease Progression, Humans, Myositis, Quality of Life, Vascular Diseases |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences |
URI: | https://discovery.ucl.ac.uk/id/eprint/10145764 |
Archive Staff Only
View Item |